Long-Term, Open-Label, Safety Study of Edivoxetine as Adjunctive Treatment for Adult Patients with Major Depressive  Disorder Who Were Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment in Japan

Depressive Disorder ◽

Serotonin Reuptake ◽

Adjunctive Treatment ◽

Open Label ◽

Major Depressive ◽

Safety Study ◽

Long-Term, Open-Label, Safety Study of Edivoxetine 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment

Journal of Clinical Psychopharmacology ◽

10.1097/jcp.0000000000000302 ◽

2015 ◽

Vol 35 (3) ◽

pp. 266-272 ◽

Cited By ~ 3

Author(s):

Susan G. Ball ◽

Sarah Atkinson ◽

JonDavid Sparks ◽

Mark Bangs ◽

Celine Goldberger ◽

...

Keyword(s):

Depressive Disorder ◽

Serotonin Reuptake ◽

Adjunctive Treatment ◽

Open Label ◽

Major Depressive ◽

Safety Study ◽

Once Daily ◽

Efficacy Outcomes From 3 Clinical Trials of Edivoxetine as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment

The Journal of Clinical Psychiatry ◽

10.4088/jcp.14m09619 ◽

2016 ◽

Vol 77 (05) ◽

pp. 635-642 ◽

Cited By ~ 5

Author(s):

Susan G. Ball ◽

Margaret B. Ferguson ◽

James M. Martinez ◽

Beth A. Pangallo ◽

E. Serap Monkul Nery ◽

...

Keyword(s):

Clinical Trials ◽

Depressive Disorder ◽

Reuptake Inhibitor ◽

Serotonin Reuptake ◽

Selective Serotonin ◽

Adjunctive Treatment ◽

Major Depressive ◽

A double-blind, placebo-controlled study of edivoxetine as an adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment

Journal of Affective Disorders ◽

10.1016/j.jad.2014.06.006 ◽

2014 ◽

Vol 167 ◽

pp. 215-223 ◽

Cited By ~ 9

Author(s):

Susan Ball ◽

Mary Anne Dellva ◽

Deborah N. D'Souza ◽

Lauren B. Marangell ◽

James M. Russell ◽

...

Keyword(s):

Depressive Disorder ◽

Serotonin Reuptake ◽

Adjunctive Treatment ◽

Controlled Study ◽

Major Depressive ◽

Double Blind ◽

Double Blind Placebo ◽

Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics

The Pharmacogenomics Journal ◽

10.1038/tpj.2012.32 ◽

2012 ◽

Vol 13 (5) ◽

pp. 456-463 ◽

Cited By ~ 42

Author(s):

Y Ji ◽

J M Biernacka ◽

S Hebbring ◽

Y Chai ◽

G D Jenkins ◽

...

Keyword(s):

Depressive Disorder ◽

Functional Genomics ◽

Reuptake Inhibitor ◽

Serotonin Reuptake ◽

Selective Serotonin ◽

Major Depressive ◽

Genome Wide ◽

Neuroendocrine, biochemical and pharmacokinetic effects of a long-term treatment with the selective serotonin reuptake inhibitor (SSRI) citalopram in major depressive disorder

European Neuropsychopharmacology ◽

10.1016/s0924-977x(01)80132-2 ◽

2001 ◽

Vol 11 ◽

pp. S187

Author(s):

G. Nikisch ◽

A. Czernik ◽

A.A. Mathé ◽

J. Diegmann ◽

M. Amey ◽

...

Keyword(s):

Depressive Disorder ◽

Reuptake Inhibitor ◽

Serotonin Reuptake ◽

Term Treatment ◽

Selective Serotonin ◽

Major Depressive ◽

Long Term Treatment

Safety and tolerability of edivoxetine as adjunctive treatment to selective serotonin reuptake inhibitor antidepressants for patients with major depressive disorder

Drugs in Context ◽

10.7573/dic.212279 ◽

2015 ◽

Vol 4 ◽

pp. 1-10 ◽

Cited By ~ 2

Author(s):

James Martinez ◽

Margaret Ferguson ◽

Beth Pengallo ◽

Tina Oakes ◽

JonDavid Sparks ◽

...

Keyword(s):

Depressive Disorder ◽

Reuptake Inhibitor ◽

Serotonin Reuptake ◽

Selective Serotonin ◽

Adjunctive Treatment ◽

Major Depressive

Association of brain-derived neurotrophic factor valine to methionine polymorphism with sexual dysfunction following selective serotonin reuptake inhibitor treatment in female patients with major depressive disorder

Asia-Pacific Psychiatry ◽

10.1111/appy.12210 ◽

2015 ◽

Vol 8 (4) ◽

pp. 260-268

Author(s):

Nur Elia Nazree ◽

Zahurin Mohamed ◽

Gavin P. Reynolds ◽

Shamsul Mohd Zain ◽

Ruziana Masiran ◽

...

Keyword(s):

Sexual Dysfunction ◽

Depressive Disorder ◽

Reuptake Inhibitor ◽

Neurotrophic Factor ◽

Serotonin Reuptake ◽

Brain Derived Neurotrophic Factor ◽

Major Depressive ◽

Effects of selective serotonin reuptake inhibitor treatment on plasma oxytocin and cortisol in major depressive disorder

BMC Psychiatry ◽

10.1186/1471-244x-13-124 ◽

2013 ◽

Vol 13 (1) ◽

Cited By ~ 25

Author(s):

Charlotte Keating ◽

Tye Dawood ◽

David A Barton ◽

Gavin W Lambert ◽

Alan J Tilbrook

Keyword(s):

Depressive Disorder ◽

Reuptake Inhibitor ◽

Serotonin Reuptake ◽

Selective Serotonin ◽

Major Depressive ◽

HTR1A-RS6295 polymorphism and selective serotonin reuptake inhibitor treatment outcome in major depressive disorder patients

Frontiers in Pharmacology ◽

10.3389/conf.fphar.2018.63.00006 ◽

2018 ◽

Vol 9 ◽

Author(s):

Ibrahim Badamasi ◽

Johnson Stanslas ◽

Munn Sann Lye ◽

Khozirah Shaari ◽

Normala Ibrahim

Keyword(s):

Treatment Outcome ◽

Depressive Disorder ◽

Reuptake Inhibitor ◽

Serotonin Reuptake ◽

Selective Serotonin ◽

Major Depressive ◽

P.2.c.012 Adjunctive tianeptine for partial or nonresponders to selective serotonin reuptake inhibitor treatment in major depressive disorder

European Neuropsychopharmacology ◽

10.1016/s0924-977x(11)70626-5 ◽

2011 ◽

Vol 21 ◽

pp. S389-S390

Author(s):

W.M. Bahk ◽

Y.S. Woo ◽

J.H. Jeong ◽

W. Kim ◽

H.M. Sung ◽

...

Keyword(s):

Depressive Disorder ◽

Reuptake Inhibitor ◽

Serotonin Reuptake ◽

Selective Serotonin ◽

Major Depressive ◽